Company intelligence / Profile preview

Vilya

Seattle, Washington, United Statesvilyatx.com ↗

Ownership: Private
Employees: ~40
Development stage: Preclinical

Overview

Vilya has validated its foundational approach to designing novel macrocycles with atomic-level accuracy in peer-reviewed publications. The company is preclinical and has no programs in human trials yet but is advancing multiple candidates using its proprietary AI-driven platform for drug discovery targeting previously undruggable disease biology.

Therapeutic areas: Oncology
Modalities: MacrocyclesDe novo designed peptides
Industry: Biotech

Drug pipeline

2 assets

NGR-sIL-24

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Institute for Protein Design (foundational collaboration/spinout)

Beyond the preview

Go deeper on Vilya.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vilya.

Explore the full profile